Quick Answer
Cogent Biosciences, Inc. reported Stockholders Equity of $636.37 million for fiscal year 2025.
Cogent Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $636.37M | +148.3% |
| 2024 | $256.29M | -0.6% |
| 2023 | $257.80M | +0.8% |
| 2022 | $255.74M | +19.4% |
| 2021 | $214.18M | -8.7% |
| 2020 | $234.67M | +638.8% |
| 2019 | $31.76M | -47.3% |
| 2018 | $60.23M | +223.3% |
| 2017 | -$48.85M | -97.8% |
| 2016 | -$24.70M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $302.46M | -3.9% | +95.1% |
| June 30, 2025 | $155.04M | -58.5% | -29.2% |
| March 31, 2025 | $219.00M | -48.1% | -14.6% |
| December 31, 2024 | $256.29M | -0.6% | -18.6% |
| September 30, 2024 | $314.66M | +3.9% | -15.7% |
| June 30, 2024 | $373.22M | +7.1% | -11.6% |
| March 31, 2024 | $422.33M | +88.9% | +63.8% |
| December 31, 2023 | $257.80M | +0.8% | -14.9% |
- Cogent Biosciences, Inc. showed an increase of +148.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2016–2025 period, Cogent Biosciences, Inc.’s stockholders equity has grown by 2676.6% (from -$24.70 million to $636.37 million).
- The most recent figure is from Cogent Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: